Objective To explore the safety of clopidogrel and pantoprazole in treatment of coronary artery disease. Methods 120 patients with acute coronary syndrome were divided into pantoprazole group and control group in our hospital from May 2011 to July 2012. The control group was given conventional treatment, pantoprazole group was given routine treatment and pantoprazole, digestive system security and various cardiovascular safety were observed in both groups. Results Cardiovascular morbidity in Pantoprazole was less than that in the control group, the difference was statistically significant (P<0.05).Conclusion Pantoprazole did not increase the proportion of clopidogrel antiplatelet therapy in patients with cardiovascular events.% 目的探讨氯吡格雷和泮托拉唑联用治疗冠心病的安全性.方法将120例急性冠脉综合征患者分为观察组和对照组,对照组采用常规治疗,观察组在常规治疗基础上加用泮托拉唑药物治疗.观察2组患者各种消化系统副作用及心血管异常发生率.结果观察组患者消化系统副作用发生人数比对照组少,2组比较差异有统计学意义(P<0.05).结论泮托拉唑不增加氯吡格雷抗血小板治疗患者的心血管事件发生比例,且消化道副反应明显降低.
展开▼
